About Kymeratx
Kymeratx is a publicly listed company based in Cambridge (United States) founded in 2016 by Nello Mainolfi and Steven Robinette. It operates as a small molecule protein degraders are developed for various disorders. Kymeratx has raised $197 million across 4 funding rounds from investors including Bessemer Venture Partners, BlackRock and Atlas Venture. The company has 188 employees. Its chief executive is Nello Mainolfi. Its website kymeratx.com draws about 23 thousand monthly visits. Kymeratx offers products and services including KT-621 and Pipeline Therapeutics. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Kymera Therapeutics, Inc. Its competitors include Jazz Pharmaceuticals, Biogen, Revolution Medicines, Blueprint Medicines and Syndax and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Kymeratx was founded in 2016 in Cambridge, United States, within the biotechnology sector. Small molecule protein degraders are developed to target IRAK4, IRAKIMiD, and STAT3, addressing immune-inflammatory diseases, hematologic malignancies, and solid tumors. Targeted protein degradation platforms are provided, based on the ubiquitin-proteasome systems role in cellular regulation. Operations focus on therapeutic applications for these conditions.
- Headquarters Cambridge, United States
- Employees 188
- Founders Nello Mainolfi, Steven Robinette
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website kymeratx.com
- Social LinkedIn X
- Legal Name Kymera Therapeutics, Inc.
- Annual Revenue$39.21 M (USD)-16.7as on Dec 31, 2025
- Net Profit-$311.35 M (USD)-39.08as on Dec 31, 2025
- EBITDA-$337.23 M (USD)-35.25as on Dec 31, 2025
- Total Equity Funding$197M (USD)
in 4 rounds
- Latest Funding Round$150M (USD), Post-IPO
Aug 2022
- InvestorsBessemer Venture Partners
& 19 more
- Employee Count188
Products & Services of Kymeratx
Kymeratx offers a comprehensive portfolio of products and services, including KT-621 and Pipeline Therapeutics.
Oral degrader for treating Atopic Dermatitis and related conditions.
First-in-class medicines targeting disease drivers.
Funding Insights of Kymeratx
Kymeratx has successfully raised a total of $197M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $197M
- Total Rounds 4
- Last Round Post-IPO — $150M
- First Round $30M
(Oct 2017)
- Investors Count 20
All 4 funding rounds of Kymeratx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $150M | Post-IPO | – | – | |
| Mar 2020 | $102M | Series C | – | Redmile Group, Foresite Capital | |
| Nov 2018 | $65M | Series B | – | 6 Dimensions Capital, Bessemer Venture Partners | |
| Oct 2017 | $30M | Series A | – | Atlas Venture |
20 investors in total: 20 institutional.
Investors in Kymeratx
Kymeratx has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Bessemer Venture Partners, BlackRock and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | – | foresitecapital.com | New York, United States | |
Biotech startups are funded by this venture capital firm. | – | boxercap.com | San Diego, United States | |
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Early-stage life sciences investments are targeted in the healthcare sector. | – | lillyventures.com | Indianapolis, United States | |
Venture capital investments are facilitated by Amgen-backed entity. | – | amgenbd.com | Thousand Oaks, United States | |
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | – | 6dimensionscapital.com | Pudong, China | |
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Life-Sciences focused Early stage Corporate VC Firm investing in the US | – | sanofiventures.com | Paris, France |
Investor details for Kymeratx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kymeratx
142 people are tracked at Kymeratx (90 in leadership, 15 in board & advisors, 37 in team); the tracked headcount is 188.
| Name | Role | Group |
|---|---|---|
Nello Mainolfi | Co-Founder & CEO | Leadership |
Steven Robinette | Co-Founder | Leadership |
Aimee Mishkin | VP, Regulatory Affairs | Leadership |
John Traverse | Vice President | Leadership |
Jared Gollob | Chief Medical Officer | Leadership |
Christine Klaus | Associate Director - Translational Medicine | Leadership |
Alexia Pico | Associate Director, Quality Systems | Leadership |
Bruce Jacobs | CFO | Leadership |
Jolly Bhatia | VP, Quality | Leadership |
Dapeng Chen | Senior Director, DMPK | Leadership |
Nichole O'Connell | Director | Leadership |
Nancy Dumont | Director, In Vivo Pharmacology | Leadership |
Joseph D. Growney | Executive Director, Cellular And In Vivo Pharmacology | Leadership |
Deborah Hilliard | Senior Director, Translational Medicine Operations | Leadership |
Karen Weisbach | VP, People & Culture | Leadership |
Xiumin Liu | Associate Director | Leadership |
Guang Liu | Senior Director, Cellular Assays | Leadership |
Dirk Walther | Associate Director | Leadership |
Julia Cleary | Executive Business Partner | Research & Corporate Strategy | Leadership |
Kate Lipford | Sr Director, Head Of Clinical Operations | Leadership |
122 more people are available in the full profile.
Complete people profiles for Kymeratx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kymeratx
Kymeratx is a publicly listed company on the NASDAQ with ticker symbol KYMR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Aug 2020
- Listed onNASDAQ: KYMR
- Listed entityKymera Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS5015751044
- Share price$106.68 (-4.82% on the day) · 2026-10-13
- Market capitalisation$8.87B
- EPS (diluted, trailing year)$-3.24
- Volume (last session)779,110
Financials of Kymeratx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $39.2M | -$311.4M | -$337.2M |
| 2024 | $47.1M | -$223.9M | -$249.3M |
| 2023 | $78.6M | -$147.0M | -$162.0M |
| 2022 | $46.8M | -$154.8M | -$158.3M |
| 2021 | $72.8M | -$100.2M | -$98.1M |
Detailed financial statements for Kymeratx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kymeratx
4 dated milestones of Kymeratx across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Kymeratx is founded.
- Funding First funding round of $30.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $150.0M.
Competitors of Kymeratx
Kymeratx has 9 listed competitors in our database, 9 of them funded. They include Jazz Pharmaceuticals, Biogen, Revolution Medicines, Blueprint Medicines and Syndax, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. |
Detailed competitors of Kymeratx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kymeratx
The website of Kymeratx (kymeratx.com) receives about 22.7K visits a month and ranks #950,688 among all websites worldwide, #1,155 in Biotechnology and Pharmaceuticals.
- Monthly visits22.7K
▼ 19.4% vs previous month
- Unique visitors11.3K
per month
- Global rank#950,688
among all websites
- Category rank#1,155
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit2.7
- Average visit1 min 47 sec
- DevicesDesktop 59% · Mobile 41%
Websites whose visitors overlap most with Kymeratx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sherlock.bio | 100% | 2.8K | #4,929,420 | View details | |
| ornatx.com | 98% | 4.4K | #3,250,511 | View details | |
| bioagilytix.com | 96% | 41.6K | #919,146 | View details | |
| dynotx.com | 96% | 14.4K | #2,089,404 | View details | |
| cuebiopharma.com | 96% | 4.9K | #7,063,180 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Kymeratx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Kymeratx (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kymeratx
Complete news archive for Kymeratx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kymeratx
Kymeratx was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Kymeratx is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Nello Mainolfi is the current CEO of Kymeratx. They have also founded this company.
Kymeratx is a funded company, having raised a total of $197M across 4 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Oct 2017.
Kymeratx has 188 employees.
Annual revenue of Kymeratx is $39.21M as on Dec 31, 2025.
Kymeratx was founded in 2016 in Cambridge, United States, within the biotechnology sector. Small molecule protein degraders are developed to target IRAK4, IRAKIMiD, and STAT3, addressing immune-inflammatory diseases, hematologic malignancies, and solid tumors. Targeted protein degradation platforms are provided, based on the ubiquitin-proteasome systems role in cellular regulation. Operations focus on therapeutic applications for these conditions.
Kymeratx's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
Kymeratx offers KT-621 and Pipeline Therapeutics.
Yes, Kymeratx is publicly traded on NASDAQ under the ticker symbol KYMR.
Kymeratx has 20 investors. Key investors include Bessemer Venture Partners, BlackRock, Atlas Venture, Aju IB Investment, and Redmile Group.
Kymeratx operates through Kymera Therapeutics, Inc..